search
Back to results

A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient

Primary Purpose

Hemophilia

Status
Recruiting
Phase
Phase 1
Locations
Korea, Republic of
Study Type
Interventional
Intervention
MG1113
Sponsored by
GC Biopharma Corp
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hemophilia focused on measuring MG1113, Hemophilia

Eligibility Criteria

19 Years - 60 Years (Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male severe hemophilia A or B patients (FVIII or FIX activity <1%) aged 19-60 years (both inclusive) at screening

    • Patients without inhibitors against FVIII or FIX (having difficulty in their Self-injection of current standard treatment regimen) OR
    • Patients with inhibitors who has a positive inhibitor result of confirmed human factor VIII or IX with an inhibitor titer(≥ 0.6 BU) and failed after ITI treatment or not undergoing ITI
  2. ≥50 kg in weight with calculated BMI between 18.5 and 29.9 kg/m^2 (BMI = (Weight [kg])/(height [m])^2)
  3. Documentation of ≥4 bleeding episodes (any type or location of bleeds, treated or not) within 6 months prior to screening
  4. Agree to use medically acceptable adequate dual contraceptive methods (condom, vasectomy, spermicide, oral contraceptives, intrauterine device, and complete sexual abstinence, etc.) and not to donate sperm until 60 days after administration of the investigational product
  5. Voluntarily decided to participate in the study and provided written consent to follow precautions after receiving a detailed explanation on this study and fully understanding the information

Exclusion Criteria:

  1. Congenital or acquired anticoagulant disorders other than hemophilia A or B, or conditions of other diseases that increase the risk of bleeding or thrombus (e.g., autoimmune disease)
  2. Be at risk of venous thromboembolism or thrombotic microangiopathy per investigator's judgment or have related medical history or family history
  3. Be at risk of cardia and/or coronary disease per investigator's judgment or have related medical history or family history
  4. Risk factors for venous or arterial disease (e.g., uncontrolled hypertension, uncontrolled diabetes)
  5. Any of the following results from laboratory tests:

    • AST(sGOT) or AST(sGPT) > 3 x UNL
    • Total bilirubin > 2 mg/mL
    • Hb < 9.0 g/dL
    • Absolute Neutrophil Count < 1500 /μL
    • Platelet count < 10^5 /μL
    • Have hepatitis B (HBs Ag positive) or C (anti-HCV positive), or have HIV positive test result If the anti-HCV antibody test is positive, the positive hepatitis virus result must be confirmed by a quantitative HCV RNA test
    • Serum Creatinine > 1.5 x Upper limit of normal (ULN)
  6. Known or suspected hypersensitivity to the IP or its components
  7. Treatment history due to symptoms of fever within 28 days of IP administration or any surgery planned during the study period
  8. Clinically significant active chronic disease
  9. Subjects who refuse the following wash-out times of Factor VIII, Factor IX, and bypassing agent from the time of first IP administration (Factor VIII: 72 hrs, Factor IX: 96 hrs, Bypassing agent e.g., rFVIIa or aPCC: 96 hrs)
  10. Received immune tolerance induction within 30 days prior to administration of the investigational product
  11. Received emicizumab within 30 days prior to administration of the investigational product
  12. Currently using systemic immunomodulator treatment (e.g., Corticosteroid*, IVIG, interferon or rituximab)

    *High-dose corticosteroids (it is allowed to administer corticosteroid equivalent to up to 20mg/kg daily based on Prednisolone, but if a dose of more is continuously administered in excess of 14 days, it is considered as high dose, such case is excluded from this study. However, inhaled, intranasal, and topical administration of corticosteroids is allowed irrespective of the dose.)

  13. Participated in another clinical trial within 30 days of investigational product administration
  14. Determined to be ineligible to participate in the study per investigator's judgment due to other reasons including the laboratory test results

Sites / Locations

  • GC Biopharma Corp.Recruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Active Comparator

Active Comparator

Arm Label

Cohort 1 (2.0 mg/kg, once weekly)

Cohort 2 (A mg/kg, once weekly)

Cohort 3 (B mg/kg, once weekly)

Arm Description

Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody Each vial contains 1mL of study drug The subjects will be treated with 2.0 mg/kg once weekly in cohort 1.

Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody Each vial contains 1mL of study drug The subjects will be treated with A mg/kg once weekly in cohort 2. The Dose A mg/kg will be determined based on the safety, PK, and PD data obtained from previous dose level (cohort 1).

Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody Each vial contains 1mL of study drug The subjects will be treated with B mg/kg once weekly in cohort 3. The Dose B mg/kg will be determined based on the safety, PK, and PD data obtained from previous dose level (cohort 2).

Outcomes

Primary Outcome Measures

Number of subject with Adverse events, Adverse Drug Reactions, Serious adverse events and Adverse event of special interest (AESI)
Incidence of Adverse events, Adverse Drug Reactions, Serious adverse events and Adverse event of special interest (AESI)
Severity of Adverse events, Adverse Drug Reactions, Serious adverse events and Adverse event of special interest (AESI)
Incidence of injection site reaction
Severity of injection site reaction
Number of subjects with abnormal Physical examination
Number of subjects with abnormal 12-lead ECG (Ventricular rate in beat/min, Interval for PR in msec, QRS in msec, QTc in msec)
Number of subjects with abnormal Vital signs (Blood pressure in mmHg, Pulse rate in beats/min, Respiration rate in breaths/min, Body temperature in ℃)
Incidence of clinically significant laboratory value abnormalities

Secondary Outcome Measures

Pharmacokinetic assessment - Cmax (Peak plasma concentration)
Pharmacokinetic assessment - Cmin (Minimum plasma concentration)
Pharmacokinetic assessment - AUC (Area under the plasma concentration versus time curve)
Pharmacokinetic assessment - Tmax (Time to maximum plasma concentration after administration)
Pharmacokinetic assessment - half-life (T1/2; the time required to reduce the plasma concentration by half)
Pharmacokinetic assessment - CL/F (apparent clearance)
Pharmacokinetic assessment - Vd/F (apparent volume of distribution)
Pharmacokinetic assessment - Accumulation Index (AUCtau_multiple dose/AUCtau_single dose)
Pharmacodynamic assessment - Free TFPI in plasma in ng/mL
Pharmacodynamic assessment - Residual TFPI activity in unit/mL
Pharmacodynamic assessment - Diluted PT in sec
Pharmacodynamic assessment - Thrombin generation (Lag time in min)
Pharmacodynamic assessment - Thrombin generation (Peak generation in nM)
Pharmacodynamic assessment - Thrombin generation (Endogenous thrombin generation potential [ETP] in nM*min)
Pharmacodynamic assessment - Pro-coagulant effect (D-dimer in ug/mL)
Pharmacodynamic assessment - Pro-coagulant effect (Fibrinogen in mg/dL)
Pharmacodynamic assessment - Pro-coagulant effect (Prothrombin fragments 1+2 in pmol/L)
Immunogenicity assessment - Any formation of anti-drug antibody (ADA) to MG1113
Efficacy Evaluation - Incidence of new bleeding episode

Full Information

First Posted
July 21, 2022
Last Updated
August 24, 2022
Sponsor
GC Biopharma Corp
search

1. Study Identification

Unique Protocol Identification Number
NCT05493631
Brief Title
A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient
Official Title
A Phase 1b, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous MG1113 in Patients With Severe Hemophilia
Study Type
Interventional

2. Study Status

Record Verification Date
August 2022
Overall Recruitment Status
Recruiting
Study Start Date
August 24, 2022 (Actual)
Primary Completion Date
July 31, 2024 (Anticipated)
Study Completion Date
December 31, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
GC Biopharma Corp

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to assess the safety and tolerability, pharmacokinetics and pharmacodynamics of subcutaneous MG1113 in the multiple ascending dose study in patients with severe hemophilia.
Detailed Description
This is a repeat-dose study that assign 5 subjects in each cohort to explore the safety, tolerability, PK, and PD of the study drug by sequentially increasing the study drug. The route of administration is subcutaneous (SC) injection. Dose escalation will be decided after checking the safety and tolerability at the previous dose to the extent not exceeding the criteria for discontinuation of dose escalation. The dose escalation will be decided by the Steering Committee and Data and Safety Monitoring Boards (DSMB) in the evaluation of the safety and tolerability data obtained from each cohort after repeated administration of MG1113. The subjects will be treated with 2.0 mg/kg once weekly for 8 weeks in cohort 1. Visit window of ±1 day (calculated from Day1) are allowed for the dosing schedule after first IP administration (Day 1). But next scheduled IP administration must be kept in mind to ensure subjects will not have more than 8 days in between IP dosing interval. The next dose level (Dose A and B) will be determined based on the safety, PK, and PD data obtained from previous dose level. If a criterion of discontinuation of dose escalation is fulfilled, discussion about dose escalation is available for next cohort. The dose selection and escalation will be finally determined from the Steering Committee and DSMB. The safety, tolerability, PK, and PD data obtained from all subjects up to Cohort 3 will be evaluated by the Steering Committee and Data and Safety Monitoring Boards (DSMB).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemophilia
Keywords
MG1113, Hemophilia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Cohort 1 (2.0 mg/kg, once weekly)
Arm Type
Active Comparator
Arm Description
Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody Each vial contains 1mL of study drug The subjects will be treated with 2.0 mg/kg once weekly in cohort 1.
Arm Title
Cohort 2 (A mg/kg, once weekly)
Arm Type
Active Comparator
Arm Description
Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody Each vial contains 1mL of study drug The subjects will be treated with A mg/kg once weekly in cohort 2. The Dose A mg/kg will be determined based on the safety, PK, and PD data obtained from previous dose level (cohort 1).
Arm Title
Cohort 3 (B mg/kg, once weekly)
Arm Type
Active Comparator
Arm Description
Anti-tissue factor pathway inhibitor (TFPI) recombinant antibody Each vial contains 1mL of study drug The subjects will be treated with B mg/kg once weekly in cohort 3. The Dose B mg/kg will be determined based on the safety, PK, and PD data obtained from previous dose level (cohort 2).
Intervention Type
Biological
Intervention Name(s)
MG1113
Intervention Description
MG1113 subcutaneous (SC) injection
Primary Outcome Measure Information:
Title
Number of subject with Adverse events, Adverse Drug Reactions, Serious adverse events and Adverse event of special interest (AESI)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Incidence of Adverse events, Adverse Drug Reactions, Serious adverse events and Adverse event of special interest (AESI)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Severity of Adverse events, Adverse Drug Reactions, Serious adverse events and Adverse event of special interest (AESI)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Incidence of injection site reaction
Time Frame
Study Day 1 to Day 57 visit
Title
Severity of injection site reaction
Time Frame
Study Day 1 to Day 57 visit
Title
Number of subjects with abnormal Physical examination
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Number of subjects with abnormal 12-lead ECG (Ventricular rate in beat/min, Interval for PR in msec, QRS in msec, QTc in msec)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Number of subjects with abnormal Vital signs (Blood pressure in mmHg, Pulse rate in beats/min, Respiration rate in breaths/min, Body temperature in ℃)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Incidence of clinically significant laboratory value abnormalities
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Secondary Outcome Measure Information:
Title
Pharmacokinetic assessment - Cmax (Peak plasma concentration)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Pharmacokinetic assessment - Cmin (Minimum plasma concentration)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Pharmacokinetic assessment - AUC (Area under the plasma concentration versus time curve)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Pharmacokinetic assessment - Tmax (Time to maximum plasma concentration after administration)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Pharmacokinetic assessment - half-life (T1/2; the time required to reduce the plasma concentration by half)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Pharmacokinetic assessment - CL/F (apparent clearance)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Pharmacokinetic assessment - Vd/F (apparent volume of distribution)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Pharmacokinetic assessment - Accumulation Index (AUCtau_multiple dose/AUCtau_single dose)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Pharmacodynamic assessment - Free TFPI in plasma in ng/mL
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Pharmacodynamic assessment - Residual TFPI activity in unit/mL
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Pharmacodynamic assessment - Diluted PT in sec
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Pharmacodynamic assessment - Thrombin generation (Lag time in min)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Pharmacodynamic assessment - Thrombin generation (Peak generation in nM)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Pharmacodynamic assessment - Thrombin generation (Endogenous thrombin generation potential [ETP] in nM*min)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Pharmacodynamic assessment - Pro-coagulant effect (D-dimer in ug/mL)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Pharmacodynamic assessment - Pro-coagulant effect (Fibrinogen in mg/dL)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Pharmacodynamic assessment - Pro-coagulant effect (Prothrombin fragments 1+2 in pmol/L)
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Immunogenicity assessment - Any formation of anti-drug antibody (ADA) to MG1113
Time Frame
Through study completion (Study Day 1 to Day 78 visit)
Title
Efficacy Evaluation - Incidence of new bleeding episode
Time Frame
Study Day 1 to Day 57 visit

10. Eligibility

Sex
Male
Gender Based
Yes
Gender Eligibility Description
Only Male severe hemophilia A or B patients will be enrolled.
Minimum Age & Unit of Time
19 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male severe hemophilia A or B patients (FVIII or FIX activity <1%) aged 19-60 years (both inclusive) at screening Patients without inhibitors against FVIII or FIX (having difficulty in their Self-injection of current standard treatment regimen) OR Patients with inhibitors who has a positive inhibitor result of confirmed human factor VIII or IX with an inhibitor titer(≥ 0.6 BU) and failed after ITI treatment or not undergoing ITI ≥50 kg in weight with calculated BMI between 18.5 and 29.9 kg/m^2 (BMI = (Weight [kg])/(height [m])^2) Documentation of ≥4 bleeding episodes (any type or location of bleeds, treated or not) within 6 months prior to screening Agree to use medically acceptable adequate dual contraceptive methods (condom, vasectomy, spermicide, oral contraceptives, intrauterine device, and complete sexual abstinence, etc.) and not to donate sperm until 60 days after administration of the investigational product Voluntarily decided to participate in the study and provided written consent to follow precautions after receiving a detailed explanation on this study and fully understanding the information Exclusion Criteria: Congenital or acquired anticoagulant disorders other than hemophilia A or B, or conditions of other diseases that increase the risk of bleeding or thrombus (e.g., autoimmune disease) Be at risk of venous thromboembolism or thrombotic microangiopathy per investigator's judgment or have related medical history or family history Be at risk of cardia and/or coronary disease per investigator's judgment or have related medical history or family history Risk factors for venous or arterial disease (e.g., uncontrolled hypertension, uncontrolled diabetes) Any of the following results from laboratory tests: AST(sGOT) or AST(sGPT) > 3 x UNL Total bilirubin > 2 mg/mL Hb < 9.0 g/dL Absolute Neutrophil Count < 1500 /μL Platelet count < 10^5 /μL Have hepatitis B (HBs Ag positive) or C (anti-HCV positive), or have HIV positive test result If the anti-HCV antibody test is positive, the positive hepatitis virus result must be confirmed by a quantitative HCV RNA test Serum Creatinine > 1.5 x Upper limit of normal (ULN) Known or suspected hypersensitivity to the IP or its components Treatment history due to symptoms of fever within 28 days of IP administration or any surgery planned during the study period Clinically significant active chronic disease Subjects who refuse the following wash-out times of Factor VIII, Factor IX, and bypassing agent from the time of first IP administration (Factor VIII: 72 hrs, Factor IX: 96 hrs, Bypassing agent e.g., rFVIIa or aPCC: 96 hrs) Received immune tolerance induction within 30 days prior to administration of the investigational product Received emicizumab within 30 days prior to administration of the investigational product Currently using systemic immunomodulator treatment (e.g., Corticosteroid*, IVIG, interferon or rituximab) *High-dose corticosteroids (it is allowed to administer corticosteroid equivalent to up to 20mg/kg daily based on Prednisolone, but if a dose of more is continuously administered in excess of 14 days, it is considered as high dose, such case is excluded from this study. However, inhaled, intranasal, and topical administration of corticosteroids is allowed irrespective of the dose.) Participated in another clinical trial within 30 days of investigational product administration Determined to be ineligible to participate in the study per investigator's judgment due to other reasons including the laboratory test results
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Yoonjung Choi
Phone
82-31-260-9143
Email
choistella@gccorp.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eun-Jin Choi
Organizational Affiliation
Daegu Catholic University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
GC Biopharma Corp.
City
Yongin-si
State/Province
Gyeonggi-do
ZIP/Postal Code
16924
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yoonjung Choi

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient

We'll reach out to this number within 24 hrs